Source link : https://www.newshealth.biz/health-news/met-inhibitor-increases-osimertinib-activity-in-egfr-advanced-nsclc/
Adding a mutation-specific targeted drug to osimertinib (Tagrisso) substantially increased the objective response rate (ORR) in newly diagnosed EGFR-mutant, MET-aberrant non-small cell lung cancer (NSCLC), a small randomized trial showed. ORR increased from 60.9% with osimertinib alone to 90.5% with the addition of the MET-selective tyrosine kinase inhibitor (TKI) savolitinib. The disease control rate increased […]
Author : News Health
Publish date : 2024-09-10 20:08:15
Copyright for syndicated content belongs to the linked Source.
Categories